Switch theme
Sign up to access all valuation multiples
Nanjing King-Friend Biochemical Pharmaceutical Co Ltd is a China-based company engaged in the research and development, import and export of medicines and health products. The main products of the company are Heparin sodium and low molecular weight heparin. Geographically, the business activities are carried out through China and it exports the product mainly to the European and American countries.
2000
n/a
LTM Revenue $627M
LTM EBITDA $176M
$2.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nanjing King-Friend has a last 12-month revenue (LTM) of $627M and a last 12-month EBITDA of $176M.
In the most recent fiscal year, Nanjing King-Friend achieved revenue of $548M and an EBITDA of $173M.
Nanjing King-Friend expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nanjing King-Friend valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $627M | XXX | $548M | XXX | XXX | XXX |
| Gross Profit | $252M | XXX | $237M | XXX | XXX | XXX |
| Gross Margin | 40% | XXX | 43% | XXX | XXX | XXX |
| EBITDA | $176M | XXX | $173M | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 32% | XXX | XXX | XXX |
| EBIT | $157M | XXX | $128M | XXX | XXX | XXX |
| EBIT Margin | 25% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $133M | XXX | $115M | XXX | XXX | XXX |
| Net Margin | 21% | XXX | 21% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $144M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Nanjing King-Friend's stock price is CNY 11 (or $2).
Nanjing King-Friend has current market cap of CNY 17.4B (or $2.4B), and EV of CNY 17.5B (or $2.4B).
See Nanjing King-Friend trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.4B | $2.4B | XXX | XXX | XXX | XXX | $0.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Nanjing King-Friend has market cap of $2.4B and EV of $2.4B.
Nanjing King-Friend's trades at 4.5x EV/Revenue multiple, and 14.1x EV/EBITDA.
Equity research analysts estimate Nanjing King-Friend's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nanjing King-Friend has a P/E ratio of 18.3x.
See valuation multiples for Nanjing King-Friend and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.4B | XXX | $2.4B | XXX | XXX | XXX |
| EV (current) | $2.4B | XXX | $2.4B | XXX | XXX | XXX |
| EV/Revenue | 3.9x | XXX | 4.5x | XXX | XXX | XXX |
| EV/EBITDA | 13.9x | XXX | 14.1x | XXX | XXX | XXX |
| EV/EBIT | 15.5x | XXX | 19.1x | XXX | XXX | XXX |
| EV/Gross Profit | 9.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 18.3x | XXX | 21.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 17.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNanjing King-Friend's last 12 month revenue growth is 25%
Nanjing King-Friend's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Nanjing King-Friend's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nanjing King-Friend's rule of X is 90% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Nanjing King-Friend and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 25% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Growth | 27% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 23% | XXX | 57% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 90% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nanjing King-Friend acquired XXX companies to date.
Last acquisition by Nanjing King-Friend was XXXXXXXX, XXXXX XXXXX XXXXXX . Nanjing King-Friend acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Nanjing King-Friend founded? | Nanjing King-Friend was founded in 2000. |
| Where is Nanjing King-Friend headquartered? | Nanjing King-Friend is headquartered in China. |
| Is Nanjing King-Friend publicy listed? | Yes, Nanjing King-Friend is a public company listed on SHG. |
| What is the stock symbol of Nanjing King-Friend? | Nanjing King-Friend trades under 603707 ticker. |
| When did Nanjing King-Friend go public? | Nanjing King-Friend went public in 2017. |
| Who are competitors of Nanjing King-Friend? | Similar companies to Nanjing King-Friend include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Nanjing King-Friend? | Nanjing King-Friend's current market cap is $2.4B |
| What is the current revenue of Nanjing King-Friend? | Nanjing King-Friend's last 12 months revenue is $627M. |
| What is the current revenue growth of Nanjing King-Friend? | Nanjing King-Friend revenue growth (NTM/LTM) is 25%. |
| What is the current EV/Revenue multiple of Nanjing King-Friend? | Current revenue multiple of Nanjing King-Friend is 3.9x. |
| Is Nanjing King-Friend profitable? | Yes, Nanjing King-Friend is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Nanjing King-Friend? | Nanjing King-Friend's last 12 months EBITDA is $176M. |
| What is Nanjing King-Friend's EBITDA margin? | Nanjing King-Friend's last 12 months EBITDA margin is 28%. |
| What is the current EV/EBITDA multiple of Nanjing King-Friend? | Current EBITDA multiple of Nanjing King-Friend is 13.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
